Future of local bone regeneration - Protein versus gene therapy

被引:82
作者
Fischer, J. [2 ]
Kolk, A. [1 ]
Wolfart, St. [2 ]
Pautke, C. [1 ]
Warnke, P. H. [4 ,5 ]
Plank, C. [3 ]
Smeets, R. [6 ]
机构
[1] Tech Univ Munich, Dept Oral & Maxillofacial Surg, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] RWTH Aachen Univ Hosp, Dept Prosthodont, D-52074 Aachen, Germany
[3] Tech Univ Munich, Inst Expt Oncol & Therapy Res, Klinikum Rechts Isar, D-81675 Munich, Germany
[4] Univ Kiel, Dept Oral & Maxillofacial Surg, D-24105 Kiel, Germany
[5] Bond Univ, Fac Hlth Sci & Med, Gold Coast, Qld, Australia
[6] RWTH Aachen Univ Hosp, Dept Oral & Maxillofacial Surg, D-52074 Aachen, Germany
关键词
Bone morphogenic protein; Gene transfer; Bone regeneration; Drug delivery; Nanotechnology; SIZE CALVARIAL DEFECT; MARROW STROMAL CELLS; IN-VIVO; MORPHOGENETIC PROTEIN; ADENOASSOCIATED VIRUS; ADENOVIRUS VECTORS; STEM-CELLS; RETROVIRAL VECTOR; PERIOSTEAL CELLS; FRACTURE REPAIR;
D O I
10.1016/j.jcms.2010.03.016
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The most promising attempts to achieve bone regeneration artificially are based on the application of mediators such as bone morphogenetic proteins (BMPs) directly to the deficient tissue site. BMPs, as promoters of the regenerative process, have the ability to induce de novo bone formation in various tissues, and many animal models have demonstrated their high potential for ectopic and orthotopic bone formation. However, the biological activity of the soluble factors that promote bone formation in vivo is limited by diffusion and degradation, leading to a short half-life. Local delivery remains a problem in clinical applications. Several materials, including hydroxyapatite, tricalcium phosphate, demineralised bone matrices, poly-lactic acid homo- and heterodimers, and collagen have been tested as carriers and delivery systems for these factors in a sustained and appropriate manner. Unfortunately these delivery vehicles often have limitations in terms of biodegradability, inflammatory and immunological rejection, disease transmission, and most importantly, an inability to provide a sustained, continuous release of these factors at the region of interest. In coping with these problems, new approaches have been established: genes encoding these growth factor proteins can be delivered to the target cells. In this way the transfected cells serve as local "bioreactors", as they express the exogenous genes and secrete the synthesised proteins into their vicinity. The purpose of this review is to present the different methods of gene versus growth factor delivery in tissue engineering. Our review focuses on these promising and innovative methods that are defined as regional gene therapy and provide an alternative to the direct application of growth factors. Various advantages and disadvantages of non-viral and viral vectors are discussed. This review identifies potential candidate genes and target cells, and in vivo as well as ex vivo approaches for cell transduction and transfection. In explaining the biological basis, this paper also refers to current experimental and clinical applications. (C) 2010 European Association for Cranio-Maxillo-Facial Surgery.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 141 条
[51]  
HORISAKA Y, 1991, CLIN ORTHOP RELAT R, P303
[52]  
Howell TH, 1997, INT J PERIODONT REST, V17, P125
[53]   Long-term in vivo gene expression via delivery of PEI-DNA condensates from porous polymer scaffolds [J].
Huang, YC ;
Riddle, K ;
Rice, KG ;
Mooney, DJ .
HUMAN GENE THERAPY, 2005, 16 (05) :609-617
[54]   Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells [J].
Ito, H ;
Goater, JJ ;
Tiyapatanaputi, P ;
Rubery, PT ;
O'Keefe, RJ ;
Schwarz, EM .
GENE THERAPY, 2004, 11 (01) :34-41
[55]   Coxsackievirus and adenovirus receptor (CAR)-positive immature osteoblasts as targets of adenovirus-mediated gene transfer for fracture healing [J].
Ito, T ;
Tokunaga, K ;
Maruyama, H ;
Kawashima, H ;
Kitahara, H ;
Horikoshi, T ;
Ogose, A ;
Hotta, Y ;
Kuwano, R ;
Katagiri, H ;
Endo, N .
GENE THERAPY, 2003, 10 (18) :1623-1628
[56]   Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer [J].
Jane, JA ;
Dunford, BA ;
Kron, A ;
Pittman, DD ;
Sasaki, T ;
Li, JZ ;
Li, HW ;
Alden, TD ;
Dayoub, H ;
Hankins, GR ;
Kallmes, DF ;
Helm, GA .
MOLECULAR THERAPY, 2002, 6 (04) :464-470
[57]   Tissue engineering and regenerative medicine [J].
Jenkins, DD ;
Yang, GP ;
Lorenz, HP ;
Longaker, MT ;
Sylvester, KG .
CLINICS IN PLASTIC SURGERY, 2003, 30 (04) :581-+
[58]   Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery [J].
Jeon, Oju ;
Song, Su Jin ;
Yang, Hee Seok ;
Bhang, Suk-Ho ;
Kang, Sun-Woong ;
Sung, Mi Ae ;
Lee, Jong Ho ;
Kim, Byung-Soo .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 369 (02) :774-780
[59]   Gene therapy of bone morphogenetic protein for periodontal tissue engineering [J].
Jin, QM ;
Anusaksathien, O ;
Webb, SA ;
Rutherford, RB ;
Giannobile, WV .
JOURNAL OF PERIODONTOLOGY, 2003, 74 (02) :202-213
[60]  
Kaigler D, 2001, J Dent Educ, V65, P456